WASHINGTON (Reuters) – A team of American scientists have developed a DNA vaccine that has had a test that has helped to prevent both types of toxic proteins that are associated with Alzheimer's disease and may be preparing & The way for a clinical trial.
A new study by the Peter Gold Foundation in collaboration with the Southwest Medical Center of the University of Texas shows that the vaccine, provided by the skin, stimulates the immune response to reduce the accumulation of TAO harmful and beta- Amyloid "- without causing severe swelling to the brain due to antibody pre-treatment in some patients.
"This study ends in a decade of research that has repeatedly shown that this vaccine can be effectively and safely targeted in animal models that are believed to cause Alzheimer's disease," says Dr Roger Rosenberg, organizational director of the University of Utah Alzheimer's Center. Express his belief in the method of scientists to develop clinical tests on people.
The study shows how the vaccine that contains the DNA encoding part of beta amyloid also reduces the process of collecting the "tywyn" protein among the mice most vulnerable to Alzheimer's disease. In addition, the vaccine causes a different immune response that could be safe for people, Similar immune responses were shown in rabbits and monkeys .
The vaccine comes in a short list of promising antibody therapies that have aimed at protecting against both types of protein that kill the cells of the brain when circulating in blood plaques and interventions on Alzheimer's patients' brain .
The latest study found that the vaccine had resulted in a 40% reduction in amyloid beta plaques and a 50% reduction in the Tau protein with no negative immune response .